Rallybio Corporation filed a Form 8-K on November 4, 2026, disclosing stockholder approval of the Avenzo Therapeutics 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the company's annual meeting, both contingent on completion of a pending merger with Avenzo.

Key Highlights

  • Annual Meeting Date: Rallybio held its annual meeting of stockholders on November 4, 2026, the same date as the event reported.
  • Record Date Shares: As of the September 11, 2026 record date, 5,312,584 shares of common stock were outstanding and entitled to vote, of which 4,790,320 shares were represented by proxy or attendance.
  • 2026 Equity Plan Reserve: The initial share reserve under the 2026 Equity Incentive Plan will equal 18% of the combined company's common stock issued and outstanding immediately after the effective time of the Merger.
  • Annual Automatic Increase: The 2026 Equity Incentive Plan share reserve will automatically increase on January 1 of each year from 2027 through 2036 by 5% of Fully Diluted Shares on the preceding December 31, unless the board acts to provide a lesser increase.
  • Incentive Stock Option Cap: The aggregate maximum shares issuable upon exercise of incentive stock options under the 2026 Plan is three times the Initial Share Reserve.
  • ESPP Initial Reserve: The 2026 Employee Stock Purchase Plan initial share reserve equals 1% of the combined company's common stock expected to be outstanding immediately after the Merger's effective time.
  • Merger Agreement: The plans are tied to the Agreement and Plan of Merger and Reorganization dated May 31, 2026, among Rallybio, Avenzo, and Farmington Merger Sub, Inc.

Rallybio Stockholders Vote on Merger-Linked Equity Plans at November 2026 Annual Meeting

According to the filing, Rallybio Corporation (NASDAQ:RLYB) held its annual stockholder meeting on November 4, 2026, at which stockholders approved two equity compensation plans connected to the company's pending merger with Avenzo Therapeutics, Inc. Both plans were approved contingent on completion of the Merger, under which Farmington Merger Sub, Inc., a wholly owned subsidiary of Rallybio, would merge with and into Avenzo, leaving Avenzo as a wholly owned subsidiary of Rallybio. The Merger Agreement is dated May 31, 2026.

The 2026 Equity Incentive Plan, the filing disclosed, will serve as the successor to Rallybio's 2021 Equity Incentive Plan. Once effective, no further grants will be made under the 2021 Plan, though outstanding awards under it will remain subject to its terms except to the extent they result in Returning Shares. The Initial Share Reserve is set at 18% of the combined company's common stock outstanding immediately after the Merger's effective time, consisting of new shares plus any Returning Shares that become available. Returning Shares include shares from expired, forfeited, cash-settled, or withheld awards under the 2021 Plan. The reserve will grow automatically each January 1 from 2027 through 2036 by 5% of Fully Diluted Shares, as defined in the plan to include all outstanding shares plus those issuable upon conversion or exercise of outstanding securities and rights.

The 2026 Employee Stock Purchase Plan, also approved at the meeting, will become effective immediately prior to and contingent upon the Merger's consummation. Its initial reserve equals 1% of the combined company's common stock expected to be outstanding at the Merger's effective time, with automatic annual increases on January 1 from 2027 through 2036 of the lesser of 1% of Fully Diluted Shares or three times the ESPP Initial Share Reserve. The filing noted that shares up to the maximum reserved may be used for purchases under the Section 423 component, with any remainder available for the non-Section 423 component. The company's board retains authority to reduce or eliminate any annual increase before the first day of the applicable calendar year.

What Was Disclosed

Rallybio's Form 8-K reported that stockholders approved the Avenzo 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan on November 4, 2026, both contingent on the pending Merger with Avenzo, and provided voting share counts as of the September 11, 2026 record date.